Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6643 in advanced solid tumors
NCT04900519Phase 1Unknown
- Sponsor
- Sorrento Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of STI-6643 in solid tumor (advanced stage), sponsored by Sorrento Therapeutics. Primary endpoint: Safety of STI-6643 at 31 months. Status: unknown.
02
Drugs
STI-6643
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04900519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900519.